keyword
MENU ▼
Read by QxMD icon Read
search

NATA

keyword
https://www.readbyqxmd.com/read/28337845/nurses-attitudes-towards-the-use-of-prn-psychotropic-medications-in-acute-and-forensic-mental-health-settings
#1
Lesley Barr, Dianne Wynaden, Karen Heslop
Many countries now have national mental health policies and guidelines to decrease or eliminate the use of seclusion and restraint yet the use of Pro Re Nata (PRN) medications has received less practice evaluation. This research aimed to identify mental health nurses' attitudes towards the use of PRN medications with mental health consumers. Participants were working in forensic mental health and non-forensic acute mental health settings. The "Attitudes towards PRN medication use survey" was used and data were collected online...
March 24, 2017: International Journal of Mental Health Nursing
https://www.readbyqxmd.com/read/28323678/long-time-outcome-in-patients-treated-with-ranibizumab-for-diabetic-macular-edema-a-4-year-study
#2
David Epstein, Urban Amrén
PURPOSE: To investigate the long-time visual outcome in patients with diabetic macular edema treated with ranibizumab in an ordinary clinical setting. METHODS: One hundred two eyes of 80 patients were followed for 4 years. All patients received a loading dose of 3 monthly ranibizumab 0.5-mg injections. From Month 3 to Month 48, patients received ranibizumab reinjections pro re nata based on disease activity. RESULTS: Excluding deaths, the 4-year visit was completed by 82% of the study eyes...
January 23, 2017: Retina
https://www.readbyqxmd.com/read/28318314/promising-and-established-investigators-experiences-participating-in-the-national-athletic-trainers-association-foundation-research-mentor-program-a
#3
Sara L Nottingham, Stephanie M Mazerolle, Jessica L Barrett
CONTEXT: Mentorship is a helpful resource for individuals who transition from doctoral student to tenure-track faculty member. The National Athletic Trainers' Association (NATA) Research & Education Foundation offers a Research Mentor Program to provide mentorship to promising investigators, particularly as they work to establish independent lines of research. OBJECTIVE: To gain the perspectives of promising and established investigators on their participation in the NATA Foundation Research Mentor Program...
March 20, 2017: Journal of Athletic Training
https://www.readbyqxmd.com/read/28283788/follow-up-of-oral-and-oropharyngeal-cancer-using-narrow-band-imaging-and-high-definition-television-with-rigid-endoscope-to-obtain-an-early-diagnosis-of-second-primary-tumors-a-prospective-study
#4
Giancarlo Tirelli, Marco Piovesana, Pierluigi Bonini, Annalisa Gatto, Giuseppe Azzarello, Francesca Boscolo Nata
Narrow-band imaging (NBI) is an optical technique enhancing mucosal vasculature. The aim of this study is to assess the effectiveness of rigid NBI endoscopy in the early detection of second primaries or local recurrences after treatment for oral (OSCC) and oropharyngeal squamous cell carcinoma (OPSCC), its advantage over standard white-light (WL) endoscopy, and the influence of previous radiotherapy, the learning curve, and lesion site. Between January 2013 and June 2015, 195 patients treated for OSCC or OPSCC with surgery alone (group A) or radiotherapy with or without surgery and/or chemotherapy (group B) underwent additional follow-up assessments using NBI...
March 10, 2017: European Archives of Oto-rhino-laryngology
https://www.readbyqxmd.com/read/28260852/prolongation-of-injection-interval-after-switching-therapy-from-ranibizumab-to-aflibercept-in-japanese-patients-with-macular-edema-secondary-to-branch-retinal-vein-occlusion
#5
Mizuki Tagami, Ryuto Sai, Masahide Fukuda, Atsushi Azumi
PURPOSE: This study was conducted to investigate the outcome of switching therapy from ranibizumab to aflibercept in Japanese patients with macular edema (ME) secondary to branch retinal vein occlusion (BRVO) in daily practice. MATERIALS AND METHODS: This retrospective study enrolled 15 eyes in 15 Japanese patients with ME secondary to BRVO who had been receiving a pro re nata regimen of ranibizumab and had provided written informed consent to switch to aflibercept therapy...
2017: Clinical Ophthalmology
https://www.readbyqxmd.com/read/28251811/head-to-head-comparison-of-ranibizumab-prn-versus-single-dose-dexamethasone-for-branch-retinal-vein-occlusion-comrade-b
#6
Lars-Olof Hattenbach, Nicolas Feltgen, Thomas Bertelmann, Steffen Schmitz-Valckenberg, Hüsnü Berk, Nicole Eter, Gabriele E Lang, Matus Rehak, Simon R Taylor, Armin Wolf, Claudia Weiss, Eva-Maria Paulus, Amelie Pielen, Hans Hoerauf
PURPOSE: To compare the efficacy and safety of ranibizumab 0.5 mg versus dexamethasone 0.7 mg according to their European labels in macular oedema secondary to branch retinal vein occlusion (BRVO) in a 6-month, phase IIIb, randomized trial. METHODS: Patients received either monthly ranibizumab for 3 months followed by Pro re nata (PRN) treatment (n = 126) or a sustained-release dexamethasone implant followed by PRN sham injections (n = 118). Main outcomes were mean average change in best-corrected visual acuity (BCVA) from baseline to month 1 through month 6, mean changes in BCVA and foveal centre point thickness (FCPT), and adverse events (AEs)...
March 2, 2017: Acta Ophthalmologica
https://www.readbyqxmd.com/read/28248827/ranibizumab-for-retinal-vein-occlusion-predictive-factors-and-long-term-outcomes-in-real-life-data
#7
Irini Chatziralli, George Theodossiadis, Alexandros Chatzirallis, Efstratios Parikakis, Panagiotis Mitropoulos, Panagiotis Theodossiadis
PURPOSE: The purpose of the study was to evaluate the long-term anatomical and functional outcomes in patients with retinal vein occlusion (RVO), either central retinal vein occlusion or branch retinal vein occlusion, treated with intravitreal ranibizumab and to determine the predictive factors of the final visual outcome. METHODS: This retrospective study included 54 treatment-naive patients with macular edema due to RVO (25 with central retinal vein occlusion and 29 with branch retinal vein occlusion), who were treated with intravitreal ranibizumab (3 monthly injections and pro re nata)...
February 28, 2017: Retina
https://www.readbyqxmd.com/read/28247580/analysis-of-non-pharmacological-interventions-attempted-prior-to-pro-re-nata-medication-use
#8
Krystle Martin, Vinita Arora, Ilan Fischler, Renee Tremblay
The aim of the present study was to elucidate what non-pharmacological interventions are applied by nursing staff prior to the administration of psychotropic pro re nata (PRN) medication. Best practices would instruct clinical staff to provide non-pharmacological strategies, such as de-escalation and skills coaching, as the first response to patient distress, anxiety, or agitation. Non-pharmacological strategies might be safer for patients, promote more collaborative relationships, and facilitate greater skills development for managing symptoms...
March 1, 2017: International Journal of Mental Health Nursing
https://www.readbyqxmd.com/read/28245446/retinal-nerve-fiber-loss-in-anti-vegf-therapy-for-age-related-macular-degeneration-can-be-decreased-by-anterior-chamber-paracentesis
#9
Philip Enders, Vasilena Sitnilska, Lebriz Altay, Friederike Schaub, Philipp S Muether, Sascha Fauser
PURPOSE: To analyze peripapillary retinal nerve fiber layer thickness (RNFLT) change after long-term intravitreal anti-VEGF therapy. Patients with regular anterior chamber paracentesis (ACP) prior to intravitreal injections (IVIs) were compared to those without ACP. METHODS: Neovascular age-related macular degeneration (nAMD) was treated in a pro re nata regimen with a minimum of 9 IVIs. RNFLT change was determined in spectral domain optical coherence tomography...
2017: Ophthalmologica. Journal International D'ophtalmologie
https://www.readbyqxmd.com/read/28231566/one-year-outcomes-of-1-pro-re-nata-versus-3-pro-re-nata-intravitreal-aflibercept-injection-for-neovascular-age-related-macular-degeneration
#10
Kei Takayama, Hiroki Kaneko, Tadasu Sugita, Ruka Maruko, Kyoko Hattori, Eimei Ra, Kenichi Kawano, Keiko Kataoka, Yasuki Ito, Hiroko Terasaki
PURPOSE: We compared 1-year outcomes of 1 + pro re nata (PRN) versus 3 + PRN of intravitreal aflibercept injection (IAI) for age-related macular degeneration (AMD). METHODS: Forty-two eyes with naïve AMD received 3 + PRN IAI treatment and 47 eyes with naïve AMD received 1 + PRN IAI treatment. Visual acuity (VA), central retinal thickness (CRT), and central choroidal thickness (CCT) and number of administered IAIs during 12 months were compared. RESULTS: VAs improved, and CRTs reduced significantly at any given month from baseline in both groups (p < 0...
2017: Ophthalmologica. Journal International D'ophtalmologie
https://www.readbyqxmd.com/read/28192841/6-year-results-of-cnv-secondary-to-pathological-myopia-treated-with-ranibizumab
#11
L Hefner, H Gerding
Background The current standard treatment of choroidal neovascularisation (CNV) secondary to pathological myopia (PM) is intravitreal injection of VEGF antagonists. We now present our 6-year results after treating patients with CNV secondary to PM with ranibizumab. Patients and Methods We retrospectively analysed 15 treatment-naive eyes of 13 patients (10 women, 3 men, mean age 59.2; standard deviation (SD) 11.1; range 41-78 years) with visual impairment related to CNV secondary to PM, who were treated with at least 1 injection of ranibizumab...
February 13, 2017: Klinische Monatsblätter Für Augenheilkunde
https://www.readbyqxmd.com/read/28188433/the-clinical-effectiveness-of-ranibizumab-treat-and-extend-regimen-in-namd-systematic-review-and-network-meta-analysis
#12
REVIEW
Andriy Danyliv, Julie Glanville, Rachael McCool, Alberto Ferreira, Adrian Skelly, Ruth Pulikottil Jacob
INTRODUCTION: Neovascular age-related macular degeneration (nAMD) is a chronic eye condition that causes severe deterioration of vision and ultimately blindness. Two vascular endothelial growth factor inhibitors are approved for nAMD treatment in Europe: ranibizumab and aflibercept. The European license for ranibizumab was updated with an individualized "treat and extend" (T&E) regimen, which involves more proactive treatment based on changes in best corrected visual acuity (BCVA) and/or anatomical outcomes...
February 10, 2017: Advances in Therapy
https://www.readbyqxmd.com/read/28183240/pharmacotherapy-of-persons-with-dementia-in-long-term-care-in-australia-a-descriptive-audit-of-central-nervous-system-medications
#13
Wendy Moyle, Najwan El Saifi, Brian Draper, Cindy Jones, Elizabeth Beattie, David Shum, Lukman Thalib, Cindy Mervin, Siobhan O Dwyer
BACKGROUND: Neuropsychiatric symptoms of dementia are often treated through the prescription of one or more psychotropic medications. However, limited efficacy and potential harmful side-effects has resulted in efforts to reduce the use of psychotropic medication in this population, particularly for those living in long-term care. OBJECTIVES: This study sought to describe the pattern of central nervous system medication usage in older adults with dementia living in long-term care; assess the appropriateness of prescribing against Beers criteria; and detect potential drug interactions from co-administered medications...
February 9, 2017: Current Drug Safety
https://www.readbyqxmd.com/read/28174600/does-accreditation-improve-pro-re-nata-benzodiazepines-administration-in-psychiatric-inpatients-pre-post-accreditation-medical-record-comparison
#14
Mohammed Abdullah Al-Sughayir
BACKGROUND: In psychiatric inpatients, administration of pro re nata benzodiazepines is a common practice. Benzodiazepine use is associated with potential complications of risk of abuse, cognitive impairment, and falls. An interest in accreditation is growing rapidly among many countries to enhance the quality of health care services. We aimed to investigate whether hospital accreditation drives improvements for administered pro re nata benzodiazepines in psychiatric inpatients. METHODS: The study reviewed medical records of consecutive hospital admissions for pre- and post-accreditation comparisons of PRN benzodiazepine medications in two acute mental health wards at a teaching general hospital...
2017: International Journal of Mental Health Systems
https://www.readbyqxmd.com/read/28151839/angiopoietin-like-4-correlates-with-response-to-intravitreal-ranibizumab-injections-in-neovascular-age-related-macular-degeneration
#15
Jong Ho Kim, Jae Pil Shin, In Taek Kim, Dong Ho Park
PURPOSE: To investigate whether the aqueous angiopoietin-like 4 (ANGPTL4) level correlates with clinical features in neovascular age-related macular degeneration (AMD). METHODS: The control and study groups consisted of all consecutive patients who received senile cataract surgery or intravitreal ranibizumab injection for treatment-naïve neovascular AMD, respectively. The AMD group received 3 monthly ranibizumab injections followed by monthly pro re nata for at least 12 months...
February 1, 2017: Retina
https://www.readbyqxmd.com/read/28144918/a-retrospective-study-of-ranibizumab-treatment-regimens-for-neovascular-age-related-macular-degeneration-namd-in-australia-and-the-united-kingdom
#16
Robert L Johnston, Hans-Joachim Carius, Adrian Skelly, Alberto Ferreira, Fran Milnes, Paul Mitchell
INTRODUCTION: Neovascular age-related macular degeneration (nAMD) is the leading cause of vision loss among persons aged 65 years and older. Anti-vascular endothelial growth factor (anti-VEGF) treatment is the recommended standard of care. The current study compares the effectiveness of ranibizumab in routine clinical practice in two countries that generally apply two different treatment regimens, treat-and-extend (T&E) in Australia or pro re nata (PRN) in the UK. METHODS: This retrospective, comparative, non-randomised cohort study is based on patients' data from electronic medical record (EMR) databases in Australia and the UK...
January 31, 2017: Advances in Therapy
https://www.readbyqxmd.com/read/28139100/dexamethasone-implant-with-fixed-or-individualized-regimen-in-the-treatment-of-diabetic-macular-oedema-six-month-outcomes-of-the-udbasa-study
#17
Valentina Sarao, Daniele Veritti, Claudio Furino, Ermete Giancipoli, Giovanni Alessio, Francesco Boscia, Paolo Lanzetta
PURPOSE: To evaluate a pro re nata administration of Ozurdex(®) implant versus a single administration for treating diabetic macular oedema (DME). METHODS: This exploratory study is designed as a comparative, multicentre, randomized study with a follow-up of 6 months. Patients with DME were assigned to treatment at baseline either with a single Ozurdex(®) implant during the entire six-month follow-up (fixed group) or Ozurdex(®) implant followed by retreatment on an individualized basis (PRN group)...
January 31, 2017: Acta Ophthalmologica
https://www.readbyqxmd.com/read/28139082/switching-from-pro-re-nata-to-treat-and-extend-regimen-improves-visual-acuity-in-patients-with-neovascular-age-related-macular-degeneration
#18
Line Kvannli, Jørgen Krohn
PURPOSE: To evaluate the visual outcome after transitioning from a pro re nata (PRN) intravitreal injection regimen to a treat-and-extend (TAE) regimen for patients with neovascular age-related macular degeneration (AMD). METHODS: A retrospective review of patients who were switched from a PRN regimen with intravitreal injections of bevacizumab, ranibizumab or aflibercept to a TAE regimen. The best corrected visual acuity (BCVA), central retinal thickness (CRT) and type of medication used at baseline, at the time of changing treatment regimen and at the end of the study were analysed...
January 31, 2017: Acta Ophthalmologica
https://www.readbyqxmd.com/read/28119292/intravitreal-ziv-aflibercept-for-the-treatment-of-choroidal-neovascularisation-associated-with-conditions-other-than-age-related-macular-degeneration
#19
Imoro Zeba Braimah, Michael Stewart, Chetan Videkar, Chintan J Dedhia, Jay Chhablani
AIM: To report the short-term outcomes of eyes with choroidal neovascularisation (CNV) associated with causes other than age-related macular degeneration (AMD) after treatment with intravitreal ziv-aflibercept (IVZ) injections. METHODS: This retrospective study included eyes with non-AMD-related CNV that were treated with IVZ (1.25 mg/0.05 mL) on a pro re nata basis. The primary outcome measure is the mean change in best-corrected visual acuity (BCVA) and secondary outcome measures include the mean change in central macular thickness (CMT) and adverse events...
January 24, 2017: British Journal of Ophthalmology
https://www.readbyqxmd.com/read/28114697/-strategies-of-intravitreal-injections-with-anti-vegf-pro-re-nata-versus-treat-and-extend
#20
K Hufendiek, A Pielen, C Framme
The goal of this report is to provide a review on different strategies for the use of pro re nata (PRN) and treat and extend (T&E) regimens with intravitreal anti-VEGF agents (bevacizumab, ranibizumab or aflibercept) in patients with retinal diseases such as neovascular AMD, diabetic macular oedema and macular oedema due to retinal vein occlusion. The main focus is to present the effectiveness and visual outcomes of both PRN and T&E regimens in the main pivotal trials and studies based on currently available evidence...
January 23, 2017: Klinische Monatsblätter Für Augenheilkunde
keyword
keyword
81148
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"